Aktiesnakken — November 2009
-
110 primarily i R&D og close UK sites + Dutch facility
-
gennemsnitsløn i genmab er 750K!
-
focus going forward R&D
-
hvormange arbejder med arzerra...
-
aka, er det dig man kan høre der chatter ibaggrunden på tastaturet...
-
-
mest costeffective at GSK kører forsøgene
-
studierne winder ned, og gsk tager de nye studier
-
ingen genmab folk i de nye data, det er GSK, og det er according to plan
-
Nu RA.....
-
morsø bank er i shit også mht. finanstilsynet og nedskrivninger
-
-
rimer det hele ikke med takeover/Stakeholder
-
de har ikke besluttet noget med RA fsva. subkutan vs. injektion
-
our view of the potential market has not changed
-
q1 2010 på subkutan
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind